Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nano Lett ; 18(9): 5885-5891, 2018 09 12.
Article in English | MEDLINE | ID: mdl-30141949

ABSTRACT

MicroRNA-based therapy that targets cardiac macrophages holds great potential for treatment of myocardial infarction (MI). Here, we explored whether boosting the miRNA-21 transcript level in macrophage-enriched areas of the infarcted heart could switch their phenotype from pro-inflammatory to reparative, thus promoting resolution of inflammation and improving cardiac healing. We employed laser capture microdissection (LCM) to spatially monitor the response to this treatment in the macrophage-enriched zones. MiRNA-21 mimic was delivered to cardiac macrophages post MI by nanoparticles (NPs), spontaneously assembled due to the complexation of hyaluronan-sulfate with the nucleic acid mediated by calcium ion bridges, yielding slightly anionic NPs with a mean diameter of 130 nm. Following intravenous administration, the miRNA-21 NPs were targeted to cardiac macrophages at the infarct zone, elicited their phenotype switch from pro-inflammatory to reparative, promoted angiogenesis, and reduced hypertrophy, fibrosis and cell apoptosis in the remote myocardium. Our work thus presents a new therapeutic strategy to manipulate macrophage phenotype using nanoparticle delivery of miRNA-21 with a potential for use to attenuate post-MI remodeling and heart failure.


Subject(s)
Hyaluronic Acid/analogs & derivatives , MicroRNAs/administration & dosage , Myocardial Infarction/therapy , Nanoparticles/chemistry , Animals , Female , Gene Transfer Techniques , Genetic Therapy , Laser Capture Microdissection , Macrophages/metabolism , Macrophages/pathology , Mice, Inbred C57BL , MicroRNAs/chemistry , MicroRNAs/genetics , MicroRNAs/therapeutic use , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Myocardium/metabolism , Myocardium/pathology
2.
J Control Release ; 266: 310-320, 2017 Nov 28.
Article in English | MEDLINE | ID: mdl-28987883

ABSTRACT

RNA interference (RNAi) has the potential to reversibly silence any gene with high efficiency and specificity. To fulfill the clinical potential of RNAi, delivery vehicles are required to transport the short interfering RNA (siRNA) to the site of action in the cells of target tissues. Here, we describe the features of novel liver-targeted siRNA nanoparticles (NPs), co-assembled due to the complexation of alginate sulfate (AlgS) with siRNA, mediated by calcium ions bridges (AlgS-Ca2+-siRNA NPs) and then bioconjugation of a targeting ligand onto the AlgS upon the NP surface. To gain insight into the complexation process and confirm AlgS accessibility on NP surface, we investigated different schemes for fabrication. All resulting NPs, independently of the component addition order, were of average size of 130-150nm, had surface charge of <-10mV, exhibited a similar atomic composition on their surface, were efficiently uptaken by HepG2 cells and induced approx. ~90% silencing of STAT3 gene. Ca2+ and AlgS concentrations in NPs affected cell uptake and gene silencing. Bioconjugation of N-acetylgalactosamine (GalNAc), a ligand to the asialoglycoprotein receptor (ASGPR) overexpressed on hepatocytes, was validated by XPS analysis and cell uptake by receptor-mediated mechanism. After intravenous (i.v.) injection to BALB/c mice, GalNAc-NPs were targeted to liver by a factor of ~3 with lesser renal clearance compared to non-targeted NPs. We foresee that the combined advantages of site-specific targeting and reversibility of the tri-component NPs as well as the simplicity of their fabrication make them an attractive system for targeted delivery of siRNA.


Subject(s)
Acetylgalactosamine/administration & dosage , Liver/metabolism , Nanoparticles/administration & dosage , RNA, Small Interfering/administration & dosage , Acetylgalactosamine/chemistry , Acetylgalactosamine/pharmacokinetics , Alginates/administration & dosage , Alginates/chemistry , Alginates/pharmacokinetics , Animals , Calcium/administration & dosage , Calcium/chemistry , Calcium/pharmacokinetics , Cell Survival , Female , Gene Silencing , Hep G2 Cells , Humans , Mice, Inbred BALB C , Nanoparticles/chemistry , RNA, Small Interfering/pharmacokinetics , Static Electricity
SELECTION OF CITATIONS
SEARCH DETAIL
...